Intratumoral immunotherapy: using the tumor as the remedy von Marabelle, A, Tselikas, L, de Baere, T, Houot, R

Volltext

Targeting the tumor microenvironment: removing obstruction to anticancer immune responses and immunotherapy von Pitt, J.M., Marabelle, A., Eggermont, A., Soria, J.-C., Kroemer, G., Zitvogel, L.

Volltext

Tocilizumab, an anti-IL-6 receptor antibody, to treat COVID-19-related respiratory failure: a case report von Michot, J.-M., Albiges, L., Chaput, N., Saada, V., Pommeret, F., Griscelli, F., Balleyguier, C., Besse, B., Marabelle, A., Netzer, F., Merad, M., Robert, C., Barlesi, F., Gachot, B., Stoclin, A.

Volltext

Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper von Champiat, S., Lambotte, O., Barreau, E., Belkhir, R., Berdelou, A., Carbonnel, F., Cauquil, C., Chanson, P., Collins, M., Durrbach, A., Ederhy, S., Feuillet, S., François, H., Lazarovici, J., Le Pavec, J., De Martin, E., Mateus, C., Michot, J.-M., Samuel, D., Soria, J.-C., Robert, C., Eggermont, A., Marabelle, A.

Volltext

Pattern recognition receptors: immune targets to enhance cancer immunotherapy von Shekarian, T., Valsesia-Wittmann, S., Brody, J., Michallet, M.C., Depil, S., Caux, C., Marabelle, A.

Volltext

Pembrolizumab in microsatellite instability high or mismatch repair deficient cancers: updated analysis from the phase II KEYNOTE-158 study von Maio, M., Ascierto, P.A., Manzyuk, L., Motola-Kuba, D., Penel, N., Cassier, P.A., Bariani, G.M., De Jesus Acosta, A., Doi, T., Longo, F., Miller, W.H., Oh, D.-Y., Gottfried, M., Xu, L., Jin, F., Norwood, K., Marabelle, A.

Volltext

Patterns of responses in metastatic NSCLC during PD-1 or PDL-1 inhibitor therapy: Comparison of RECIST 1.1, irRECIST and iRECIST criteria von Tazdait, M., Mezquita, L., Lahmar, J., Ferrara, R., Bidault, F., Ammari, S., Balleyguier, C., Planchard, D., Gazzah, A., Soria, J.C., Marabelle, A., Besse, B., Caramella, C.

Volltext

Biomarkers associated with checkpoint inhibitors von Manson, G., Norwood, J., Marabelle, A., Kohrt, H., Houot, R.

Volltext

Starting the fight in the tumor: expert recommendations for the development of human intratumoral immunotherapy (HIT-IT) von Marabelle, A., Andtbacka, R., Harrington, K., Melero, I., Leidner, R., de Baere, T., Robert, C., Ascierto, P.A., Baurain, J -F, Imperiale, M., Rahimian, S., Tersago, D., Klumper, E., Hendriks, M., Kumar, R., Stern, M., Öhrling, K., Massacesi, C., Tchakov, I., Tse, A., Douillard, J -Y, Tabernero, J., Haanen, J., Brody, J.

Volltext

Immune-related adverse events with immune checkpoint blockade: a comprehensive review von Michot, J.M, Bigenwald, C, Champiat, S, Collins, M, Carbonnel, F, Postel-Vinay, S, Berdelou, A, Varga, A, Bahleda, R, Hollebecque, A, Massard, C, Fuerea, A, Ribrag, V, Gazzah, A, Armand, J.P, Amellal, N, Angevin, E, Noel, N, Boutros, C, Mateus, C, Robert, C, Soria, J.C, Marabelle, A, Lambotte, O

Volltext

Challenges of phase 1 clinical trials evaluating immune checkpoint-targeted antibodies von Postel-Vinay, S., Aspeslagh, S., Lanoy, E., Robert, C., Soria, J.-C., Marabelle, A.

Volltext

Hyperprogression during immunotherapy: do we really want to know? von Champiat, S., Besse, B., Marabelle, A.

Volltext

Infectious complications associated with the use of immune checkpoint inhibitors in oncology: reactivation of tuberculosis after anti PD-1 treatment von Picchi, H., Mateus, C., Chouaid, C., Besse, B., Marabelle, A., Michot, J.M., Champiat, S., Voisin, A.L., Lambotte, O.

Volltext

Immune checkpoint inhibitor-based combinations: is dose escalation mandatory for phase I trials? von Simmet, V., Eberst, L., Marabelle, A., Cassier, P.A.

Volltext

Stability of nivolumab in its original vials after opening and handing in normal saline bag for intravenous infusion von Le Guyader, G., Vieillard, V., Mouraud, S., Do, B., Marabelle, A., Paul, M.

Volltext

Inflammatory gastrointestinal diseases associated with PD-1 blockade antibodies von Collins, M., Michot, J.M., Danlos, F.X., Mussini, C., Soularue, E., Mateus, C., Loirat, D., Buisson, A., Rosa, I., Lambotte, O., Laghouati, S., Chaput, N., Coutzac, C., Voisin, A.L., Soria, J.C., Marabelle, A., Champiat, S., Robert, C., Carbonnel, F.

Volltext

Plasma proteomics identifies leukemia inhibitory factor (LIF) as a novel predictive biomarker of immune-checkpoint blockade resistance von Loriot, Y., Marabelle, A., Guégan, J.P., Danlos, F.X., Besse, B., Chaput, N., Massard, C., Planchard, D., Robert, C., Even, C., Khettab, M., Tselikas, L., Friboulet, L., André, F., Nafia, I., Le Loarer, F., Soria, J.C., Bessede, A., Italiano, A.

Volltext

How do immune checkpoint-targeted antibodies work? The need for improved pharmacokinetic evaluation in early phase studies von Ascierto, P.A., Marabelle, A.

Volltext

Impact of acetaminophen on the efficacy of immunotherapy in cancer patients von Bessede, A., Marabelle, A., Guégan, J.P., Danlos, F.X., Cousin, S., Peyraud, F., Chaput, N., Spalato, M., Roubaud, G., Cabart, M., Khettab, M., Chaibi, A., Rey, C., Nafia, I., Mahon, F.X., Soria, J.C., Italiano, A.

Volltext

Circulating L-arginine predicts the survival of cancer patients treated with immune checkpoint inhibitors von Peyraud, F., Guégan, J.-P., Bodet, D., Nafia, I., Fontan, L., Auzanneau, C., Cousin, S., Roubaud, G., Cabart, M., Chomy, F., Le Loarer, F., Chaput, N., Danlos, F.-X., Planchard, D., Even, C., Khettab, M., Tselikas, L., Besse, B., Barlesi, F., Soria, J.-C., Marabelle, A., Bessede, A., Italiano, A.

Volltext